HomeNewsIndiaDelhi's sero-prevalence study finds 23.48% people affected by COVID-19

Delhi's sero-prevalence study finds 23.48% people affected by COVID-19

The study, which was conducted from June 27 to July 10 by the National Center for Disease Control (NCDC) in collaboration with the Delhi government, also indicated that a large number of infected persons remain asymptomatic, it said.

July 21, 2020 / 14:48 IST
Representative image

Delhi's sero-prevalence study has found that 23.48 percent of the people have been affected by COVID-19 in the city, which has several pockets of dense population, the Union Health Ministry said on Tuesday.

The study, which was conducted from June 27 to July 10 by the National Center for Disease Control (NCDC) in collaboration with the Delhi government, also indicated that a large number of infected persons remain asymptomatic, it said.

A sero-survey involves testing of blood serum of individuals to check for the prevalence of antibodies against an infection.

Coronavirus India News LIVE Updates

"The results of the sero-prevalence study show that on an average, across Delhi, the prevalence of IgG antibodies is 23.48 percent. The study also indicates that a large number of infected persons remain asymptomatic," the ministry said in a statement.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"This implies that nearly six months into the epidemic, only 23.48 pc of the people are affected in Delhi, which has several pockets of dense population," said the ministry, attributing it to efforts taken by the government to prevent the spread of infection including lockdown, containment and surveillance measures, including contact tracing and tracking, as well as citizen's compliance to COVID appropriate behaviours.

It, however, said that a significant proportion of the population is still vulnerable and therefore, the containment measures need to continue with the same rigour.

Non-pharmacological interventions such as physical distancing, use of face mask/cover, hand hygiene, cough etiquette and avoidance of crowded places etc., must be followed strictly, it underlined.

For all the 11 districts of Delhi, survey teams were formed. Blood samples were collected from selected individuals after taking written informed consent and then their sera were tested for IgG antibodies and infection using COVID KAVACH ELISA approved by the Indian Council for Medical Research.

It is one of the largest sero-prevalence studies conducted in the country using the ELISA testing.

A total of 21,387 samples were collected as per lab standards and were tested.

The tests help in identification of presence of antibodies in the general population. The test performed is not a diagnostic test but only provides information about past infection due to SARSCoV-2 in individuals who test positive, the ministry said.

According to the Health ministry's data updated at 8 am, Delhi's COVID-19 caseload increased to 1,23,747 while the death-toll rose to 3,663 on Tuesday.

Follow our full coverage of the coronavirus pandemic here.

PTI
first published: Jul 21, 2020 02:00 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
CloseOutskill Genai